Nyumbani › Burkitt Lymphoma › Ohio › Cincinnati
Majaribio ya kliniki ya Burkitt Lymphoma katika Cincinnati, OH
Masomo 12 ya Burkitt Lymphoma yanatafuta washiriki katika vituo vya Cincinnati na maeneo yake (ndani ya takriban maili 30). Fungua somo kuona nani anaweza kujiunga na jinsi ya kuwasiliana na timu ya utafiti.
Maandishi rasmi ya utafiti (Kiingereza)
Unavutia washiriki kwa utafiti hapa? Weka juu ya ukurasa huu — $99 kwa siku 30 →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
InaajiriHatua 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
InaajiriHatua 3
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · Mi 15 mbali
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
InaajiriUtafiti wa uchunguzi
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
InaajiriHatua 2
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · Mi 15 mbali
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
InaajiriHatua 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
InaajiriHatua 3
- University of Cincinnati Medical Center, Cincinnati
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
InaajiriHatua 3
- Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
InaajiriHatua 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
InaajiriHatua 3
- Cincinnati Children's Hospital Medical Center, Cincinnati
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
InaajiriHatua 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
InaajiriHatua 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
InaajiriHatua 1
- University of Cincinnati, Cincinnati
Majaribio ya Burkitt Lymphoma katika miji mingine
- Houston, TXUtafiti 21
- Milwaukee, WIUtafiti 16
- Philadelphia, PAUtafiti 16
- New York City, NYUtafiti 14
- Chicago, ILUtafiti 14
- Atlanta, GAUtafiti 12
- Seattle, WAUtafiti 11
- Durham, NCUtafiti 10
- Boston, MAUtafiti 10
- Aurora, COUtafiti 10
- Los Angeles, CAUtafiti 10
- Kansas City, MOUtafiti 10
Masomo mengine katika Cincinnati
- Saratani ya Mapafu Isiyo na Selu NdogoUtafiti 35
- Saratani (aina zote)Utafiti 27
- Saratani ya MatitiUtafiti 25
- Kushindwa kwa MoyoUtafiti 24
- Kansari ya kolorektaliUtafiti 21
- Leukemia ya Myeloid ya GhaflaUtafiti 20
- Saratani ya MetastasiUtafiti 20
- Kansari ya MayaiUtafiti 19
- Saratan ya MapafuUtafiti 19
- UnenepuUtafiti 19
- Saratani ya ProstateUtafiti 18
- Multiple MyelomaUtafiti 17
Kutoka ClinicalTrials.gov, data iliyopatikana 5 Okt 2026. Kila utafiti una masharti yake ya kufaa; timu ya utafiti huamua nani anaweza kujiunga.